These experiments were designed to define the renal disposition of pyrazinoic acid in a nonhuman primate that is phylogenetically close to man and to relate this to the effects of pyrazinoate on urate excretion. The renal clearance of pyrazinoate was almost always greater than the simultaneous glomerular filtration rate at plasma concentrations ranging from 1.9 to 960 µg/ml. Some inhibitors of tubular secretion, probenecid, MK-282 (an experimental, potent uricosuric drug), p-aminohippurate, iodopyracet, sulfinpyrazone, and mersalyl, reduced clearances of pyrazinoate to values far below filtration rate. Chlorothiazide, allopurinol, and salicylate did not. The clearance of pyrazinoate was not influenced by changes in urine flow. It is concluded that pyrazinoate is actively secreted and actively reabsorbed.
A B S T R A C T These experiments were designed to define the renal disposition of pyrazinoic acid in a nonhuman primate that is phylogenetically close to man and to relate this to the effects of pyrazinoate on urate excretion. The renal clearance of pyrazinoate was -almost always greater than the simultaneous glomerular filtration rate at plasma concentrations ranging from 1.9 to 960 Fg/ml. Some inhibitors of tubular secretion, probenecid, MK-282 (an experimental, potent uricosuric drug), p-aminohippurate, iodopyracet, sulfinpyrazone, and mersalyl, reduced clearances of pyrazinoate to values far below filtration rate. Chlorothiazide, allopurinol, and salicylate did not. The clearance of pyrazinoate was not influenced by changes in urine flow. It is concluded that pyrazinoate is actively secreted and actively reabsorbed.
Pyrazinoate had a dual effect on urate excretion. At concentrations in plasma less than 10 ug/ml there was a concentration related fall in urate/inulin clearance ratio, reaching values of 10-20% of control. Over the range of 10-100 Ihg/ml in plasma, the clearance of urate remained maximally depressed. At higher concentrations of pyrazinoate there was a concentration related increase in urate/inulin clearance ratio such that at pyrazinoate levels above 600 /tg/ml a definite uricosuric response was obtained. Prior administration of pyrazinoate to give plasma levels of 20-140 /Ag/ml completely or almost completely prevented uricosuric respones to probenecid, PAH, chlorothiazide, and sulfinpyrazone. lodopyracet, mersalyl, salicylate and N-acetyl-4-dibutylsulfamoyl-3-trifluoromethylbenzenesulfonamide (MK-282) retained significant uricosuric action, but the activities were prob-INTRODUCTION Pyrazinamide, an antituberculous drug, causes a substantial fall in the renal clearance of urate (1) and eventually hyperuricemia (2) . It is thought that the decrease in urate clearance results from selective inhibition of tubular secretion (1, 3) . In addition, it has been inferred that the difference in urate excretion before and after pyrazinamide ingestion is a minimal estimate of unidirectional urate secretion (3) . On this basis the "pyrazinamide suppression test" has been used in research on the renal defect of gout (4, 5) , the mechanisms of uricosuric drugs (6) (7) (8) , and other phenomena (9) (10) (11) (12) (13) .
Studies in lower animals (14) and man (1) indicate that pyrazinamide itself may not be the agent active in suppressing urate clearance, but that a metabolite, pyrazinoic acid, is responsible for urate retention. In several experiments with a human subject pyrazinoate appeared in body fluids with sufficient rapidity to account temporally for the effects on urate (14) . In this and another study (15) the concentrations of pyrazinoic acid in plasma did not exceed 10 Ag/ml suggesting that it is extremely potent in suppressing urate excretion.
Other observations in animals indicate that pyrazinoic acid is both secreted and reabsorbed (14) , as is uric acid (16, 17) . Moreover, there is evidence suggesting that pyrazinoic acid has a dual effect on the renal tubule, i.e. at low concentrations in plasma the compound may cause urate retention while at higher concentrations it may be uricosuric ( 14) . Since the foregoing results are potentially relevant for interpretation of the "pyrazinamide suppression test," it The Journal of Clinical Investigation Volume 52 August 1973 August -1946 August -1957 seemed desirable to obtain information on the renal disposition of pyrazinoic acid and on the renal response to various concentrations of this compound in man. Three circumstances make the acquisition of such information difficult: (a) pyrazinoic acid is not an official drug and preparations for human use are not available; (b) high doses of pyrazinoic acid produce considerable discomfort in humans (1, 14) , and (c) the in vivo rate of formation of pyrazinoic acid from pyrazinamide is slow (14, 15) and thus only a narrow range of pyrazinoate concentrations can be studied when the amide is given.
In view of recent evidence that the pattern of urate excretion in the chimpanzee is very similar to that in man (18) (19) (20) , we elected to undertake a collaborative study in the chimpanzee. The results demonstrate that pyrazinoic acid is both secreted and reabsorbed, that it is extremely potent in suppressing urate excretion and that at high concentrations it produces a uricosuric effect.
In addition, observations have been made on the interaction of pyrazinoate and other drugs influencing urate excretion.
METHODS
A total of 30 clearance experiments were performed under phencyclidine HC1 restraint in seventeen male chimpanzees (Pan troglodytes verus) weighing between 30 and 62 kg. Details of experimental technique have been described previously (18) . The experimental protocols will be apparent from the results. In all instances, pyrogen-free inulin was used to measure glomerular filtration rate (GFR).' The clearance of p-aminohippurate was determined in all experiments. Except in those instances in which PAH was used as an inhibitor of secretion or in which TmPAH was determined, the plasma concentrations of this substance were kept in the range of 1-3 mg/100 ml. Inulin, urate, and PAH were determined as previously described (18) . The analytical method for pyrazinoate (polarography) and the chromatographic, electrophoretic, and solvent partitioning procedures were identical to those reported elsewhere (14) . Ultrafiltrates of plasma were prepared by the method of Toribara, Terepka, and Dewey (21) at 37°C in an atmosphere of 5% C02-95%o oxygen.
All of the drugs used in this study are well known compounds except MK-282, the chemical name of which is N-acetyl-4-dibutylsulfamoyl-3-trifluoromethylbenzenesulfonamide. The latter is an experimental drug which is more potent than probenecid as a uricosuric agent and probably shares with probenecid the ability to suppress the secretion of PAH.
RESULTS
Binding of pyrazinoic acid to plasma proteins. Ultrafiltrates were prepared from pooled plasma samples containing from 6 to 380 tg/ml of pyrazinoate. The average ' Abbreviations used in this paper: C, clearance; GFR, glomerular filtration rate (clearance of inulin); P. not very responsive to changes in urine flow induced by an osmotic diuretic. Fig. 1 is a mass plot depicting the relationship of CPz/ GFR and the concentration of pyrazinoate in plasma. The data are only those from control periods, i.e., potential inhibitors of secretion were not present. All but a few of the points are above the line which represents the clearance ratio expected were neither secretion nor reabsorption of pyrazinoate to occur. Net tubular secretion occurs with great frequency. The mass plot does not suggest a strong relationship between clearance ratio and plasma concentration in the range covered. However, in individual experiments in which the concentration of pyrazinoate in plasma was intentionally varied there is a trend toward lower clearance at high concentrations in plasma. This trend is most easily appreciated in the higher range of concentrations. It is obvious from this figure that the substantial decrease in clearance of pyrazinoate after probenecid administration seen in Table  I cannot be attributed to minor changes in plasma level. Table III summarizes the results of fifteen experiments of the type shown in Table I . In each instance after control periods, pyrazinoate was administered and after renal function was assessed, a second drug was given. In every instance pyrazinoate exerted its characteristic inhibition of urate clearance. In most instances the clearance of pyrazinoate exceeded GFR. Several compounds, which are known to inhibit the secretion of other organic anions, probenecid (22), MK-282 (unpublished data), PAH (high concentrations) (23), iodopyracet (24) , sulfinpyrazone (25) , and mersalyl (26) depressed the clearance of pyrazinoate. Presumably most of these agents are competitive inhibitors of pyrazinoate secretion. A few compounds, chlorothiazide, allopurinol, and salicylate did not depress the renal clearance of pyrazinoate. Two of these, chlorothiazide (27) and salicylate (28) are thought to be competitors for the organic anion (hippurate) secretory mechanism and it is possible that the lack of effect on pyrazinoate secretion was due to insufficient dosage. This point was not pursued.
The depression of pyrazinoate excretion to levels less than the quantities filtered in eight of the experiments constitutes evidence for tubular reabsorption. The fact that the clearance of pyrazinoate is relatively insensitive to rate of urine flow (Table II) even when secretion is inhibited and reabsorption predominates (Table IV) practically eliminates a passive mechanism as the major component of the reabsorptive process. The physical properties of pyrazinoate are such that passive reabsorption would not be expected. The pKa of the compound is 2.92 (29) and it is poorly lipid soluble (14) . These results are consistent with those from other species in suggesting that pyrazinoate undergoes bidirectional active transport in the renal tubule (14) .
Effects on urate excretion. Several of the compounds tested as potential inhibitors of pyrazinoate secretion (Table III) are potent uricosuric agents in the chimpanzee (18) (19) (20) 30) . As already demonstrated, the uricosuric effect of probenecid is virtually prevented if pyrazinoate is administered first. Similarly, if probenecid is used first, its uricosuric effect is abolished when pyrazinoate is given subsequently (Table IV) W4 -w 700 /Ag/ml. There is evidence that uricosuric responses are related to concentrations of drugs in tubular fluid rather than in plasma (31) (32) (33) . For that reason the response of C4,/GFR has been plotted against a parameter of pyrazinoate excretion which presumably is related to the concentration of the drug at its site of action (Fig. 3) 200 400 600 800 1000 1200 1400 1600
UpZ V/GFR, a~g/ml FIGURE 3 Curate/GFR (expressed as percent of control) as a function of pyrazinoate excretion per ml of GFR.
Only those data corresponding to Ppz > 100 ,ug/ml are included (cf. Fig. 2) . Each point represents an individual clearance period. The data are from 12 experiments.
cretion by other organic anions which are themselves actively secreted. Reabsorption occurs; this is frequently seen after secretion is depressed by presumed competitive inhibitors. In view of the lack of effect of osmotic diuresis on pyrazinoate clearance, it is probable that this reabsorption is also mediated by an active transport process.
The traditional interpretation of experiments in which the administration of one organic anion depresses the secretion of another is that the anions compete for a common secretory mechanism (24) . Accordingly, the inhibition of pyrazinoate secretion by PAH and other compounds (Table III) is a manifestation of competition. The failure of pyrazinoate, at the doses employed, to inhibit PAH secretion may be taken as evidence that pyrazinoate is a poor competitor, i.e., it has a lower affinity for the secretory mechanism than does PAH. Since urate secretion is depressed by pyrazinoate it might be inferred that urate secretion is also mediated by this common mechanism. However, if this were true, PAH, the better of the two exogenous competitors for the common mechanism, should be more potent in suppressing urate secretion than is pyrazinoate. But, PAH does not reduce urate clearance. This paradox may be resolved in one of two ways. First, it is possible that there are two mechanisms for organic anion secretion. One of these would be the traditional "hippurate" mechanism which is responsible for PAH secretion and most of pyrazinoate secretion. For this mechanism pyrazinoate would be a weak inhibitor. The other mechanism would be largely responsible for the secretion of urate and it is for this transport system that pyrazinoate would be a strong inhibitor and PAH, a weak one. This hypothesis has already been invoked to Pyrazinoate, ET-rate, and Uricosuric Drugsexplain a similar discrepancy in the effects of PAH and m-hydroxybenzoate on urate excretion (35) .
An alternative proposal requires that PAH inhibit both secretion and reabsorption of urate in such a balanced way that there would be little change in urate clearance even though urate secretion were seriously impaired. Since PAH inhibits urate reabsorption in rats (36) and is faintly uricosuric in the chimpanzee (19) this proposal is not entirely unreasonable. However, in view of other evidence, we prefer the hypothesis invoking two secretory mechanisms. At low concentrations in plasma, pyrazinoate prevents mercurial-induced net secretion of urate, while PAH does not (30) . If, as we believe, the mercurial effect results from extensive inhibition of urate reabsorption, this should create a situation which would unmask extensive inhibition of secretion by low levels of PAH were it to occur.
The concentration-response curve (Fig. 2) has features in common with the corresponding curve from experiments with salicylate in man (31) . However, there are significant differences. First, the suppression of urate clearance by pyrazinoate is almost complete; the clearance is reduced by about 50% with salicylate. And second, there is a much wider separation between urate-retaining and uricosuric concentrations with pyrazinoate than with salicylate. One interpretation of this curve is that urate secretion is almost completely inhibited at low levels of pyrazinoate and that much higher concentrations of the drug are required for even small inhibition of urate reabsorption. This interpretation is in complete harmony with the assumptions underlying the "pyrazinamide suppression test" (3). The new feature, inhibition of urate reabsorption at high levels of pyrazinoate, is irrelevant to the test because of the dose of pyrazinamide usually employed. However, the suppression test carries with it an additional implication, i.e., the secretory and reabsorptive processes are virtually independent. This can only obtain if there is a unidirectional mechanism for the secretion of urate which is distal to the reabsorptive site. If secretion is proximal to or coextensive with reabsorption, it will provide additional urate for reabsorption. In such situations the change in urate excretion after pyrazinamide will be a reflection of how the reabsorptive system responds to a change in urate availability and not a quantitative reflection of the uninhibited secretory rate. Thus, it becomes pertinent to inquire into the appropriateness of a model of the nephron which places secretion of urate distal to reabsorption.
The model involving distal secretion makes it difficult to attribute the action of probenecid and some other drugs to inhibition of the reabsorption of urate. There is no apparent reason why an inhibitor of a small distal secretory mechanism should prevent (Table I) or abolish (Table IV ) the action of a drug which inhibits proximal reabsorption of much greater magnitude. In an attempt to resolve a paradox of this type it has been proposed that some uricosuric drugs stimulate secretion of urate (6) (7) (8) . Accordingly, pyrazinoate would prevent the action of probenecid to enhance secretion. Because there is fairly direct evidence that probenecid inhibits entry of urate into the tubule (37) and limits urate movement out of the tubule (36), it seems somewhat extravagant to propose this adidtional action, enhancement of secretion.
An alternative hypothesis pertinent to this paradox was offered by Amini, Petrakis, Mandel, and Doherty (38) who postulated that pyrazinamide enhanced reabsorption of urate. Accordingly, one could rationalize the failure to observe a uricosuric action with probenecid by assuming that with pyrazinoate pretreatment the enhanced reabsorption of urate is not sufficiently impaired by the usual dose of probenecid. But here again there is fairly direct evidence that pyrazinoate can diminish the ingress (14, 37) and egress (36) of urate from the tubule and the postulate of a third activity is not economical.
Since the only reasonably direct studies on the effects of drugs on transtubular movements of urate suggest inhibition of transport, either secretory or reabsorptive, we will for the rest of this discussion assume that all drugs act on urate movements only by depressing transport.
If secretion of urate is distal to reabsorption, it follows that the maximal rate of urate excretion, i.e., the rate that would obtain after complete blockade of reabsorption, would be equal to but not greater than the sum of the rate of urate filtration and the rate of excretion before blockade. After the administration of the powerfully uricosuric mercurial, mersalyl, one can observe excretory rates in excess of this sum (30) .
In summary, on the basis of these pharmacological considerations it is unlikely that urate secretion is distal to urate reabsorption. The older work (39, 40) purporting to demonstrate distal secretion of urate has not been confirmed and some of it has been criticized on technical grounds (37, 41, 42) . Accordingly, we will discard the hypothesis of distal secretion in the attempt to evaluate the effects of pyrazinoate and other drugs. This involves denying the validity of the "pyrazinamide suppression test."
The results of clearance experiments with pyrazinoate and other drugs can be accommodated by models specifying either coextensive secretion and reabsorption or reabsorption distal to secretion. As was appreciated by others, models of these types allow for more transtubular traffic of urate than is easily appreciated from clearance experiments: "It would not be surprising if the unidirectional fluxes, when measured, proved to be quite 1954 G. M. Fanelli, Jr. and I. M. Weiner high" (41) . We will use the coextensive model for illustration because we believe that it is most compatible with published results. A summary of older literature localizing secretion and reabsorption to the proximal tubule is given in reference 42; other pertinent references are 36, 37, 41, 43, and 44. There is one free flow micropuncture study in rats (45) suggesting that net secretion may be proximal to reabsorption, but in fact the two processes are coextensive (46) . Obviously at any particular level of the nephron, one or the other unidirectional flux may predominate depending on the relative activities of the two transport processes, extent of fluid reabsorption, etc. There are, in addition, some recent preliminary reports in which the results are interpretable in terms of there being two reabsorptive sites, one coextensive with the proximal secretory site and one more distal (13, 47, 48) . The existence of a small distal reabsorptive mechanism would complicate our considerations only slightly and for present purposes need not be considered further.
Since we cannot actually estimate transtubular fluxes, we have for purposes of illustration assumed that the secretory moiety is equal to the filtered load (scheme A, Fig. 4 ). This is based on the observation that the clearance ratio, Cur/GFR, may be as high as 1.98 after administration of mersalyl (30 (50, 51) . However, there is at present no reason to suspect that the processes involved are large in magnitude or that they are the sites of drug action. An extensive discussion of this phenomenon is given by Mudge, Berndt, and Valtin (52) .
